Search Results - "DeLaurentiis, Michelino"

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC) by DeLaurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Salvador, Jacot, William, Dent, Susan Faye, Martin, Miguel, Ring, Alistair E., Cottu, Paul H., Lu, Janice M., Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Ankrah, Nii, Zamagni, Claudio

“…Abstract only 1041 Background: RIBO, an oral, selective inhibitor of CDK4/6 (CDK4/6i), is approved for use in combination with endocrine therapy (ET) in women…”
Get full text

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER by Baselga, Jose, Dent, Susan Faye, Cortés, Javier, Im, Young-Hyuck, Diéras, Véronique, Harbeck, Nadia, Krop, Ian E., Verma, Sunil, Wilson, Timothy R., Jin, Huan, Wang, Lijia, Schimmoller, Frauke, Hsu, Jerry Y., He, Jing, DeLaurentiis, Michelino, Drullinsky, Pamela, Jacot, William

“…Abstract only LBA1006 Background: Taselisib, a potent, selective PI3K inhibitor, has enhanced activity in PIK3CA-MUT BC cell lines and confirmed partial…”
Get full text

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study by D'Alonzo, Alessia, Bighin, Claudia, Puglisi, Fabio, DeLaurentiis, Michelino, Fontana, Andrea, Pugliese, Palma, Arpino, Grazia, Poggio, Francesca, Vaglica, Marina, Dellepiane, Chiara, Blondeaux, Eva, Conte, Benedetta, Cognetti, Francesco, Garrone, Ornella, Pastorino, Simona, Ceppi, Marcello, Del Mastro, Lucia

“…Abstract only…”
Get full text

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) by Rugo, Hope S., Im, Seock-Ah, Wright, Gail Lynn Shaw, Escriva-de-Romani, Santiago, DeLaurentiis, Michelino, Cortes, Javier, Bahadur, Shakeela Wazeen, Haley, Barbara B., Oyola, Raul H., Riseberg, David A., Musolino, Antonino, Cardoso, Fatima, Curigliano, Giuseppe, Kaufman, Peter A., Pegram, Mark D., Edlich, Sutton, Hong, Sam, Rock, Edwin P., Gradishar, William John

“…Abstract only 1000 Background: Pretreated HER2+ MBC lacks a defined standard of care, although T is commonly used. M has similar HER2 binding and…”
Get full text

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumors by Baselga, Jose, Cortés, Javier, DeLaurentiis, Michelino, Dent, Susan, Diéras, Véronique, Harbeck, Nadia, Hsu, Jerry Y., Jin, Huan, Schimmoller, Frauke, Wilson, Timothy R., Im, Young-Hyuck, Jacot, William, Krop, Ian E, Verma, Sunil

“…Abstract only TPS1119 Background: As one of the most frequent genomic alterations in BC, PIK3CA mutations occur in ~40% of ER-positive, HER2-negative breast…”
Get full text

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial by DeLaurentiis, Michelino, Neven, Patrick, Jerusalem, Guy Heinrich Maria, Bachelot, Thomas Denis, Jacot, William, Dent, Susan Faye, Colleoni, Marco, Prat, Aleix, Martin, Miguel, Ring, Alistair E., Cottu, Paul H., Lu, Janice M., Azim, Hamdy A., Zhou, Katie, Wu, Jiwen, Zarate, Juan Pablo, Zamagni, Claudio

“…Abstract only…”
Get full text

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3 by Slamon, Dennis J., Neven, Patrick, Chia, Stephen K. L., Im, Seock-Ah, Fasching, Peter A., DeLaurentiis, Michelino, Petrakova, Katarina, Bianchi, Giulia Valeria, Esteva, Francisco J., Martin, Miguel, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Cristina Karen, Miller, Michelle Kristine, Taran, Tanya, Jerusalem, Guy Heinrich Maria

“…Abstract only…”
Get full text